SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    S. Dijkstra, P.F.A. Mulders, J.A. Schalken, Clinical use of novel urine and blood based prostate cancer biomarkers: A review, Clinical Biochemistry, 2014, 47, 10-11, 889

    CrossRef

  2. 2
    S. Velaeti, E. Dimitriadis, K. Kontogianni-Katsarou, A. Savvani, E. Sdrolia, G. Pantazi, S. Stefanakis, T. Trangas, N. Pandis, K. Petraki, Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia, Tumor Biology, 2014,

    CrossRef

  3. 3
    YanHong Yao, Haitao Wang, BaoGuo Li, Yong Tang, Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis, Tumor Biology, 2014, 35, 3, 2157

    CrossRef

  4. 4
    Luis Martínez-Piñeiro, Jack A. Schalken, Patrick Cabri, Pascal Maisonobe, Alexandre Taille, Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer, BJU International, 2014, 114, 3
  5. 5
    V. Vlaeminck-Guillem, Le test urinaire PCA3 : quelles perspectives ?, Médecine Nucléaire, 2014, 38, 1, 21

    CrossRef

  6. 6
    Carsten Stephan, Bernhard Ralla, Klaus Jung, Prostate-specific antigen and other serum and urine markers in prostate cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014, 1846, 1, 99

    CrossRef

  7. 7
    Daphne Hessels, Jack A. Schalken, Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses, Current Urology Reports, 2013, 14, 3, 214

    CrossRef